Merck Announces $6.7 Billion Acquisition of Terns Pharmaceuticals

Merck has announced a definitive agreement to acquire Terns Pharmaceuticals for $6.7 billion. This acquisition is seen as part of Merck's strategy to expand its oncology portfolio and strengthen its pipeline. The deal aligns with Merck's focus on innovative drug development. The transaction is expected to close in the fourth quarter of 2023, pending regulatory approvals.